Spada, Francesca
Campana, Davide
Lamberti, Giuseppe
Laudicella, Riccardo
Dellamano, Renato
Dellamano, Luca
Leeuwenkamp, Oscar
Baldari, Sergio
Funding for this research was provided by:
advanced accelerator applications
Article History
Received: 23 July 2021
Accepted: 12 December 2021
First Online: 24 December 2021
Declarations
:
: Not applicable due to the nature of the study.
: Not applicable as the study did not enrol human participants.
: Not applicable as the work contains no images of a human participant or original patient-level data.
: F.S. has received research support from Ipsen, Novartis, Pfizer, Advanced Accelerator Applications, and Merck for advisory boards and speaking engagements and is a principal investigator in clinical trials funded by GETNE, Incyte, and MSD. Additionally, F.S. has non-remunerated positions on the executive board of ITANET (Italian Neuroendocrine Tumor Society) and as a coordinator of the NEN AIOM guidelines.L.D. and R.D. have been providing consultancy services to Advanced Accelerator Applications/A Novartis Company, Colleretto Giacosa, Italy.O.L. is an employee of Advanced Accelerator Applications/A Novartis Company, Geneva, Switzerland, which funded the study.D.C., G.L., R.L., and S.B. declare no conflicts of interest that are relevant to the present work.